{"id":14,"date":"2016-04-05T21:59:11","date_gmt":"2016-04-05T21:59:11","guid":{"rendered":"http:\/\/projects.nib.si\/gammadeltatcells\/?page_id=14"},"modified":"2024-03-04T21:58:25","modified_gmt":"2024-03-04T20:58:25","slug":"summary","status":"publish","type":"page","link":"https:\/\/projects.nib.si\/gammadeltatcells\/summary\/","title":{"rendered":"Project overview"},"content":{"rendered":"<p class=\"ASGrantsText\"><span lang=\"EN-US\">Although Chimeric Antigen Receptor (CAR)-T cell therapy represents a paradigm shift in the treatment of certain blood cancers that do not respond to other available treatment options, major challenges remain in terms of efficacy, safety, and broad availability. One approach to address this issue is to use alternative immune cells to generate CAR-T cells. In this proposal, we focus on \u03b3\u03b4 T cells because of their unique properties. Although \u03b3\u03b4 T cells have proven to be attractive effectors for generating CAR-T cells for cancer immunotherapy, the key determinants that define successful therapeutic outcomes are much less known for \u03b4\u03b3 CAR-T cells compared to \u03b1\u03b2 CAR-T cells. This gap hinders the use of \u03b4\u03b3 CAR-T cells as a platform that can potentially be effective in situations where \u03b1\u03b2 CAR-T cells have limited activity.<\/span><\/p>\n<p>Please see section \u201c<a title=\"Permalink to Project phases and realisation\" href=\"http:\/\/projects.nib.si\/gammadeltatcells\/project-phases-and-realisation\/\" rel=\"bookmark\">Project phases and realisation<\/a>\u201d for more information.<\/p>\n<p>We are open for collaborations, if you&#8217;re interested please contact <a href=\"http:\/\/Anze.Smole@nib.si\">dr An\u017ee Smole<\/a>.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Although Chimeric Antigen Receptor (CAR)-T cell therapy represents a paradigm shift in the treatment of certain blood cancers that do not respond to other available treatment options, major challenges remain in terms of efficacy, safety, and broad availability. One approach to address this issue is to use alternative immune cells to generate CAR-T cells. In [&hellip;]<\/p>\n","protected":false},"author":3,"featured_media":0,"parent":0,"menu_order":2,"comment_status":"closed","ping_status":"closed","template":"page-fullwidth.php","meta":{"footnotes":""},"class_list":["post-14","page","type-page","status-publish","hentry"],"jetpack_sharing_enabled":true,"jetpack_shortlink":"https:\/\/wp.me\/Phau4X-e","jetpack-related-posts":[],"_links":{"self":[{"href":"https:\/\/projects.nib.si\/gammadeltatcells\/wp-json\/wp\/v2\/pages\/14","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/projects.nib.si\/gammadeltatcells\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/projects.nib.si\/gammadeltatcells\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/projects.nib.si\/gammadeltatcells\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/projects.nib.si\/gammadeltatcells\/wp-json\/wp\/v2\/comments?post=14"}],"version-history":[{"count":24,"href":"https:\/\/projects.nib.si\/gammadeltatcells\/wp-json\/wp\/v2\/pages\/14\/revisions"}],"predecessor-version":[{"id":381,"href":"https:\/\/projects.nib.si\/gammadeltatcells\/wp-json\/wp\/v2\/pages\/14\/revisions\/381"}],"wp:attachment":[{"href":"https:\/\/projects.nib.si\/gammadeltatcells\/wp-json\/wp\/v2\/media?parent=14"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}